GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (FRA:49Y) » Definitions » Other Income (Expense)

Avenue Therapeutics (FRA:49Y) Other Income (Expense) : €-0.54 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Avenue Therapeutics Other Income (Expense)?

Avenue Therapeutics's other income expense for the Avenue Therapeutics's pretax income for the three months ended in Dec. 2024 was €0.01 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.54 Mil.

Avenue Therapeutics Other Income (Expense) Historical Data

The historical data trend for Avenue Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avenue Therapeutics Other Income (Expense) Chart

Avenue Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 5.27 3.91 -0.56

Avenue Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.49 -0.64 0.07 0.02 0.01

Avenue Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avenue Therapeutics  (FRA:49Y) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Avenue Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (FRA:49Y) » Definitions » Other Income (Expense)
Comparable Companies
LADX SYRS VIRX ISCO ONCO EVFM TRVN EMMA TSOI AIBT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ATXI:USA
Address
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Website
https://www.avenuetx.com
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its current product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's Disease), intravenous tramadol (IV tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders.

Avenue Therapeutics Headlines

No Headlines